Acquirer
Lilly
Lilly appears as the named buyer in 6 recorded transactions between 2017 and 2023, most often in healthcare & life sciences.
Record
What Lilly has bought
Every recorded transaction where Lilly is the named buyer. Most private deals never disclose a consideration, so a dash is the normal case rather than a gap in the record.
| Target | Sector | Sold by | Date | Consideration |
|---|---|---|---|---|
| Sigilon | Healthcare & Life Sciences | — | 2023-06-29 | $349m |
| Akouos | Healthcare & Life Sciences | — | 2022-10-18 | $610m |
| Prevail Therapeutics | Healthcare & Life Sciences | — | 2020-12-15 | $880m |
| Disarm Therapeutics | Healthcare & Life Sciences | — | 2020-10-15 | $135m |
| AurKa Pharma | Healthcare & Life Sciences | — | 2018-05-14 | $110m |
| CoLucid Pharmaceuticals | Healthcare & Life Sciences | — | 2017-01-18 | $960m |
Compiled from an archive of 10,204 recorded transactions. This is a record of deals that were reported, not a complete history of what this company has bought, and nothing here is represented as being for sale.
Also buying
Comparable buyers
Other companies acquiring in healthcare & life sciences.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Are you an investor?
Register your mandate and we will send matching opportunities as they arise.
Register a mandateTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.